Global Linerixibat Itch Study of Efficacy and Safety in Primary Biliary Cholangitis (PBC) (GLISTEN)

PHASE3CompletedINTERVENTIONAL
Enrollment

238

Participants

Timeline

Start Date

August 27, 2021

Primary Completion Date

October 28, 2024

Study Completion Date

December 20, 2024

Conditions
Pruritus
Interventions
DRUG

Linerixibat

Participants will receive linerixibat.

DRUG

Placebo

Participants will receive placebo.

Trial Locations (114)

1118

GSK Investigational Site, Ciudad AutOnoma de Buenos Aire

1618

GSK Investigational Site, Sofia

1797

GSK Investigational Site, Sofia

3000

GSK Investigational Site, Santa Fe

4004

GSK Investigational Site, Plovdiv

9000

GSK Investigational Site, Ghent

10016

GSK Investigational Site, New York

14080

GSK Investigational Site, Mexico City

19104

GSK Investigational Site, Philadelphia

20089

GSK Investigational Site, Rozzano MI

20142

GSK Investigational Site, Milan

20900

GSK Investigational Site, Monza

22100

GSK Investigational Site, Nahariya

27560

GSK Investigational Site, Morrisville

27710

GSK Investigational Site, Durham

28007

GSK Investigational Site, Madrid

28041

GSK Investigational Site, Madrid

30100

GSK Investigational Site, Pilsen

33012

GSK Investigational Site, Hialeah

33032

GSK Investigational Site, Miami

33136

GSK Investigational Site, Miami

34362

GSK Investigational Site, Haifa

37024

GSK Investigational Site, Negrar Verona

38043

GSK Investigational Site, Grenoble

39216

GSK Investigational Site, Jackson

41013

GSK Investigational Site, Seville

41126

GSK Investigational Site, Modena

43210

GSK Investigational Site, Columbus

45147

GSK Investigational Site, Essen

48149

GSK Investigational Site, Münster

48377

GSK Investigational Site, Detroit

58100

GSK Investigational Site, Holon

59037

GSK Investigational Site, Lille

64020

GSK Investigational Site, Monterrey

75012

GSK Investigational Site, Paris

75203

GSK Investigational Site, Dallas

75390

GSK Investigational Site, Dallas

76100

GSK Investigational Site, Rehovot

77030

GSK Investigational Site, Houston

80131

GSK Investigational Site, Napoli

80907

GSK Investigational Site, Colorado Springs

84101

GSK Investigational Site, Beersheba

90048

GSK Investigational Site, Los Angeles

90127

GSK Investigational Site, Palermo

91054

GSK Investigational Site, Erlangen

91120

GSK Investigational Site, Jerusalem

94010

GSK Investigational Site, Créteil

94143

GSK Investigational Site, San Francisco

95817

GSK Investigational Site, Davis

100032

GSK Investigational Site, Beijing

100069

GSK Investigational Site, Beijing

111123

GSK Investigational Site, Moscow

119121

GSK Investigational Site, Moscow

130021

GSK Investigational Site, Changchun

200127

GSK Investigational Site, Shanghai

210003

GSK Investigational Site, Nanjing

300000

GSK Investigational Site, Tianjin

330006

GSK Investigational Site, Nanchang

400042

GSK Investigational Site, Chongqing

443063

GSK Investigational Site, Samara

510630

GSK Investigational Site, Guangzhou

524000

GSK Investigational Site, Zhanjiang

630005

GSK Investigational Site, Novosibirsk

650000

GSK Investigational Site, Kemerovo

18618686

GSK Investigational Site, Botucatu

90035003

GSK Investigational Site, Porto Alegre

68198-2000

GSK Investigational Site, Omaha

C1061AAS

GSK Investigational Site, Buenos Aires

C1181ACI

GSK Investigational Site, Capital Federal

C1056ABI

GSK Investigational Site, Ciudad Autonoma de Bueno

S2002KDT

GSK Investigational Site, Rosario

B2900DMH

GSK Investigational Site, San Nicolás

70.335-900

GSK Investigational Site, Brasília

40110-160

GSK Investigational Site, Salvador

T6G 2X8

GSK Investigational Site, Edmonton

M5G 2C4

GSK Investigational Site, Toronto

708 52

GSK Investigational Site, Ostrava

140 21

GSK Investigational Site, Prague

115 27

GSK Investigational Site, Athens

00168

GSK Investigational Site, Roma

791-0295

GSK Investigational Site, Ehime

918-8503

GSK Investigational Site, Fukui

730-8619

GSK Investigational Site, Hiroshima

734-8551

GSK Investigational Site, Hiroshima

006-8555

GSK Investigational Site, Hokkaido

300-0028

GSK Investigational Site, Ibaraki

760-8557

GSK Investigational Site, Kagawa

259-1143

GSK Investigational Site, Kanagawa

390-8621

GSK Investigational Site, Nagano

856-8562

GSK Investigational Site, Nagasaki

634-8522

GSK Investigational Site, Nara

431-3192

GSK Investigational Site, Shizuoka

113-8603

GSK Investigational Site, Tokyo

162-8655

GSK Investigational Site, Tokyo

173-8606

GSK Investigational Site, Tokyo

06700

GSK Investigational Site, Mexico City

42-217

GSK Investigational Site, Częstochowa

40-659

GSK Investigational Site, Katowice

41-400

GSK Investigational Site, Mysłowice

03-712

GSK Investigational Site, Warsaw

51-162

GSK Investigational Site, Wroclaw

08036

GSK Investigational Site, Barcelona

RG24 9AA

GSK Investigational Site, Basingstoke

CB2 0QQ

GSK Investigational Site, Cambridge

DH1 5TW

GSK Investigational Site, Durham

HU3 2JZ

GSK Investigational Site, Hull

L9 7AL

GSK Investigational Site, Liverpool

E1 1FR

GSK Investigational Site, London

NW3 2QG

GSK Investigational Site, London

NE4 6BE

GSK Investigational Site, Newcastle upon Tyne

PL6 8DH

GSK Investigational Site, Plymouth

RG1 5AN

GSK Investigational Site, Reading Berkshire

SO16 6YD

GSK Investigational Site, Southampton

RH1 5RH

GSK Investigational Site, Surrey

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT04950127 - Global Linerixibat Itch Study of Efficacy and Safety in Primary Biliary Cholangitis (PBC) (GLISTEN) | Biotech Hunter | Biotech Hunter